| 1. |
Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am, 2003, 30(4): 765-776.
|
| 2. |
Dalbagni G, Herr H. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am, 2000, 27(1): 137-146.
|
| 3. |
Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology, 1997, 50(3): 349-353.
|
| 4. |
Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology, 2003, 3: 25.
|
| 5. |
Jadad AR, Moore RA, Carroll D, et a1. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
|
| 6. |
Wiener HG, Mian C, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol, 1998, 159(6): 1876-1880.
|
| 7. |
Leyh H, Marberger M, Conort P, et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol, 1999, 35(1): 52-56.
|
| 8. |
Pode D, Shapiro A, Wald M, et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol, 1999, 161(2): 443-446.
|
| 9. |
Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol, 1999, 161(2): 388-394.
|
| 10. |
Sharma S, Zippe CD, Pandrangi L, et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol, 1999, 162(1): 53-57.
|
| 11. |
Giannopoulos A, Manousakas T, Mitropoulos D, et al. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology, 2000, 55(6): 871-875.
|
| 12. |
Poulakis V, Witzsch U, De Vries R, et al. A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int, 2001, 88(7): 692-701.
|
| 13. |
Raitanen MP, Marttila T, Nurmi M, et al. Human complement factor H related protein test for monitoring bladder cancer. J Urol, 2001, 165(2): 374-377.
|
| 14. |
van Rhijn BW, Lurkin I, Kirkels WJ, et al. Microsatellite analysis– DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer, 2001, 92(4):768-775.
|
| 15. |
Boman H, Hedelin H, Holmang S. Four bladder tumor markershave a disappointingly low sensitivity for small size and low grade recurrence. J Urol, 2002, 167(1): 80-83.
|
| 16. |
葉敏, 沈海波, 黃云騰, 等. 幾種新瘤標對膀胱癌早期診斷價值的比較. 臨床泌尿外科雜志, 2004, 19(3): 151-153.
|
| 17. |
孫羿, 何輝, 馬強, 等. 膀胱腫瘤抗原和透明質酸等七項腫瘤標志物在膀胱腫瘤診斷中的應用價值.中華醫學雜志, 2005, 85(35): 2507-2512.
|
| 18. |
Sun Y, He DL, Ma Q, et al. Comparison of seven screening methodsin the diagnosis of bladder cancer. Chin Med J (Engl), 2006, 119(21): 1763-1771.
|
| 19. |
Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. ClinCancer Res, 1998, 4(10): 2511-2520.
|
| 20. |
Lokeshwar VB, Schroeder GL, Selzer MG, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer, 2002, 95(1): 61-7221 Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Croat Med J, 2003, 44(5): 639-650.
|
